ALOX12 and metabolic dysfunction-associated steatohepatitis: IMA-1, identified as a small molecule, has been confirmed to be capable of interrupting the ALOX12–ACC1 axis via directly binding to a pocket in ALOX12, thereby preventing the progression of NASH with milder side effects (Zhang et al., 2021a).